Treatment of cerebrovascular disease

Details Treatment of cerebrovascular disease Treatment of cerebrovascular disease

2005-03-01

2005-03-01

Spivack, Phyllis (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S321000, C514S233500, C514S253040

Reexamination Certificate

active

06861439

ABSTRACT:
A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

REFERENCES:
patent: 3206463 (1965-09-01), Baetz
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4569938 (1986-02-01), Esanu
patent: 4569939 (1986-02-01), Esanu
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4730042 (1988-03-01), Hege et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Koltringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254557 (1993-10-01), Buckle et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Barbul et al.
patent: 5733916 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
patent: 5944020 (1999-08-01), Markov et al.
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 6310093 (2001-10-01), Newcomb
patent: 6339085 (2002-01-01), Haque
patent: 831350 (1976-01-01), None
patent: 863754 (1978-05-01), None
patent: 561 183 (1975-04-01), None
patent: 1 958 226 (1970-05-01), None
patent: 24 61 742 (1976-07-01), None
patent: 37 05 549 (1988-09-01), None
patent: 43 44 751 (1995-06-01), None
patent: 0 121 036 (1984-10-01), None
patent: 0 144 051 (1985-06-01), None
patent: 0 270 026 (1988-06-01), None
patent: 0 416 248 (1991-03-01), None
patent: 0 891 719 (1999-01-01), None
patent: 846376 (1941-03-01), None
patent: 1323941 (1963-12-01), None
patent: 5552 (1967-12-01), None
patent: 6453 (1968-12-01), None
patent: 1579544 (1969-08-01), None
patent: 2034 539 (1970-12-01), None
patent: 2101010 (1972-03-01), None
patent: 2255883 (1975-07-01), None
patent: 2428640 (1980-01-01), None
patent: 1 013 939 (1965-12-01), None
patent: 1172800 (1969-12-01), None
patent: 1 201 014 (1970-08-01), None
patent: 1 297 080 (1972-11-01), None
patent: 1 360 536 (1974-07-01), None
patent: 1 493 993 (1977-12-01), None
patent: 2 254 556 (1992-10-01), None
patent: WO 8300085 (1983-01-01), None
patent: WO 9119500 (1991-12-01), None
patent: WO 9418965 (1994-09-01), None
patent: WO 9819690 (1998-05-01), None
patent: WO 99003365 (1999-01-01), None
patent: WO 9953928 (1999-10-01), None
Aybak, M. et al., “Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension”,Drug Res.,vol. 45, No. 12, pp. 1271-1273 (1995).
“B Vitamins May Cut Heart Disease Risk”,Harvard Health Letter,1 page (1998).
Baliga, B. et al., “Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine”,Endocrine Practice,vol. 6, No. 6, pp. 435-441 (Nov./Dec. 2000).
Barrett, S., “Homocysteine: A Cardiovascular Risk Factor Worth Considering”, http://www.quackwatch.com/03HealthPromotion/homocysteine.html, 2 pages (©1997).
Bernstein, A., “Vitamin B6in Clinical Neurology”,Annals of New York Academy of Sciences,vol. 585, pp. 250-260 (1990).
Berger, A.R. et al., “Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity”,Neurology,vol. 42, No. 7, pp. 1367-1370 (Jul. 1992).
Bhagavan, H. et al., “Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5′-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats”,Pediat. Res.,vol. 10, pp. 730-732 (1976).
Bode, W. et al., “Pyridoxal-5′-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6”,Nutr.,vol. 121, No. 11, pp. 1738-1745 (Nov. 1991).
Chasan-Taber, L. et al., “A Prospective Study of Folate and Vitamin B6and Risk of Myocardial Infarction in US Physicians”,Journal of the American College of Nutrition,vol. 15, No. 2, pp. 136-143 (Apr. 1996).
Cho, Y. et al., “In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis”,J. Nutr.,vol. 120, pp. 258-265 (1990).
Ellis, J. et al., “Prevention of Myocardial Infarction by Vitamin B6”,Res. Commun. Molec. Pathol. Pharmacol.,vol. 89, No. 2, pp. 208-220 (Aug. 1995).
Folsom, A. et al., “Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study”,Circulation,vol. 98, pp. 204-210 (Jul. 21, 1998).
Harada, K. et al., “Studies on Vitamin B6-(IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration”,Vitamins Journal of the Vitamin Society of Japan,vol. 45, No. 2, pp. 69-75 (Feb. 1972).
Hathcock, J., “Vitamins and minerals: efficacy and safety”,Am J Clin Nutr,vol. 66, pp. 427 -437 (1997).
Hoover, D.M. et al., “Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs”,Vet. Pathol.,vol. 18, pp. 769-777 (1981).
Kok, F. et al., “Low Vitamin B6Status in Patients with Acute Myocardial Infarction”,Am. J. Cardiol.,vol. 63, pp. 513-516 (Mar. 1, 1989).
Korytnyk et al. Schiff Bases of Pyriodoxal: Their Structure and Stabilization of their Ring-Chain Tautomeric Forms by Acylation, Tetrahedron, 26 (23), 5415-25 (1982).
Krinke, G. et al., “Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6in Rat Primary Sensory Neurons”,J. Neuropathol. Exp. Neurol.,vol. 44, No. 7, pp. 117-129 (Mar. 1985).
Kubyshkin, V. et al., “Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correlation in dilated and hypertrophic cardiomyopathy”,Abstract,1 pg. (1989).
Lal, K. et al., “Hypotensive action of 5-HT receptor agonists in the vitamin B6-deficient hypertensive rat&

Affiliated with

Also associated with

Rating

Treatment of cerebrovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of cerebrovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cerebrovascular disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3429048